Five thousand patients have been treated with OssDsign AB’s nanosynthetic bone graft, OssDsign Catalyst, the Swedish company announced today. 
 
The product has gained significant traction in the U.S. market since its August 2021 launch. “With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it’s accelerating. This is a significant leap from the earlier announcements of 2,000 patients treated in September 2023 and 1,000 patients in May 2023, demonstrating the rapid pace with which we are building our orthobiologics business,” OssDsign CEO Morten Henneveld said.
 
OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue in the body. Twelve-month results from the TOP FUSION clinical study, published in the Biomedical Journal of Scientific & Technical Research, show a 93 % spinal fusion rate as well as improvements in quality of life and pain following surgery with OssDsign Catalyst.

Last year, the company released a new size of OssDsign Catalyst to the U.S. market. The additional volume option of 1 cubic centimetre (cc) completes the existing product range of 10cc, 5cc and 2.5cc, and broadened access to new procedures in both cervical spine and smaller extremities. “We are excited to announce that our new smaller size of OssDsign Catalyst is now available in the U.S. We see a rapidly growing interest in our innovative nanosynthetic bone graft, and by this extension of the Catalyst product range, more patients can be helped. For OssDsign this means that we can further increase our commercial opportunity,” Henneveld stated at the time.
 
The 1cc option addition completes the OssDsign Catalyst size range, giving the company competitive strength in hospital approval processes and allowing for deeper usage in already approved hospitals. The 1cc size also allows the company to target ambulatory surgery centers (ASCs), which engage a large number of surgeons from different hospitals, thereby increasing product awareness among a broader surgeon population. 
 
OssDsign develops and provides next-generation orthobiologics products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.